| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/21/2007 | CA2633023A1 Polycyclic indazole derivatives that are erk inhibitors |
| 06/21/2007 | CA2632930A1 Diphenyl urea derivatives |
| 06/21/2007 | CA2632925A1 Diphenyl urea derivatives |
| 06/21/2007 | CA2632910A1 Biphenyl derivatives as selective agonists of gamma rar receptor |
| 06/21/2007 | CA2632899A1 Biphenyl derivatives as selective agonists of gamma rar receptors |
| 06/21/2007 | CA2632894A1 Use of a dermatological composition comprising an association of hydroquinone, fluocinolone acetonide and tretinoin for treating skin hyperpigmentation following psoriasis or eczema |
| 06/21/2007 | CA2632893A1 (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders |
| 06/21/2007 | CA2632837A1 Anti-myosin va sirna and skin depigmentation |
| 06/21/2007 | CA2632618A1 Demethylpenclomedine analogs and their use as anticancer agents |
| 06/21/2007 | CA2632616A1 Topical glucocorticosteroid formulations |
| 06/21/2007 | CA2632607A1 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
| 06/21/2007 | CA2632603A1 Dibenzonaphthyridine derivatives and methods of use thereof |
| 06/21/2007 | CA2632550A1 Medium chain triglycerides for preserving cognitive function |
| 06/21/2007 | CA2632466A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| 06/21/2007 | CA2632437A1 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumours |
| 06/21/2007 | CA2632030A1 Compounds which modulate the cb2 receptor |
| 06/21/2007 | CA2632028A1 Rifamycin analogs and uses thereof |
| 06/21/2007 | CA2632027A1 Diaza heterocyclic sulfonamide derivatives and their uses |
| 06/21/2007 | CA2631954A1 Uses of rifamycins |
| 06/21/2007 | CA2631949A1 Micronization method for preparing virtually anhydrous tiotropium bromide monohydrate |
| 06/21/2007 | CA2631907A1 Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
| 06/21/2007 | CA2631891A1 Chitin derivatives for hyperlipidemia |
| 06/21/2007 | CA2631853A1 Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors |
| 06/21/2007 | CA2631813A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof |
| 06/21/2007 | CA2631737A1 Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| 06/21/2007 | CA2631695A1 Pyrrolo[2,3-b]pyridine derivatives as h3 receptor modulators |
| 06/21/2007 | CA2631694A1 Pyrrolo[2,3-c]pyridine derivatives |
| 06/21/2007 | CA2631658A1 Salts of clopidogrel with polyanions and their use for manufacturing pharmaceutical formulations |
| 06/21/2007 | CA2631654A1 [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders |
| 06/21/2007 | CA2631641A1 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib |
| 06/21/2007 | CA2631498A1 Hcv prodrug formulation |
| 06/21/2007 | CA2631391A1 Aqueous-alcoholic depigmenting gel |
| 06/21/2007 | CA2631342A1 Novel n-(fluoro-pyrazinyl)-phenylsulfonamid.es as moodulators of chemokine receptor ccr4. |
| 06/21/2007 | CA2631051A1 Organic compounds |
| 06/21/2007 | CA2631034A1 Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| 06/21/2007 | CA2630849A1 Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile |
| 06/21/2007 | CA2630823A1 Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
| 06/21/2007 | CA2629778A1 Use of pyrrolo [2 , 3-b] pyridines to prepare a medicament for treating pain |
| 06/21/2007 | CA2629432A1 Control of intraocular pressure using alk5 modulation agents |
| 06/21/2007 | CA2629263A1 Controlling toxicity of aminoquinoline compounds |
| 06/21/2007 | CA2629046A1 Abuse resistant transmucosal drug delivery device |
| 06/21/2007 | CA2628952A1 Aspartic protease inhibitors |
| 06/21/2007 | CA2627722A1 Cetp inhibitors |
| 06/21/2007 | CA2611586A1 Pharmaceutical formulations of amyloid inhibiting compounds |
| 06/20/2007 | EP1798285A1 Methods and medicament for inhibition the expression of a defined gene |
| 06/20/2007 | EP1798243A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors |
| 06/20/2007 | EP1798242A2 New anti-GF-IR antibodies and their applications |
| 06/20/2007 | EP1798235A1 Acid addition salt of irinotecan |
| 06/20/2007 | EP1798234A1 Pharmaceutical composition comprising temozolomide ester |
| 06/20/2007 | EP1798233A1 Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
| 06/20/2007 | EP1798232A1 Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 06/20/2007 | EP1798231A2 Intermediate products for the preparation of antibacterial compounds |
| 06/20/2007 | EP1798230A1 Substituted alkylamine derivatives and methods of use |
| 06/20/2007 | EP1798229A1 Substituted biphenyl derivative |
| 06/20/2007 | EP1798227A1 Serotonin 5-ht3 receptor agonist |
| 06/20/2007 | EP1798226A1 Triazole derivative |
| 06/20/2007 | EP1798225A1 Nucleoside analogues or salts thereof |
| 06/20/2007 | EP1798223A2 Aryl sulfonamides |
| 06/20/2007 | EP1798221A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 06/20/2007 | EP1798220A1 Dibenzene derivatives as calcium channel blockers |
| 06/20/2007 | EP1798219A1 Contrast agents |
| 06/20/2007 | EP1798217A1 Anticancer agents based on regulation of protein prenylation |
| 06/20/2007 | EP1797902A2 Particles for inhalation having sustained release properties |
| 06/20/2007 | EP1797901A1 Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| 06/20/2007 | EP1797899A1 Preventive and remedy for collagen or elastin metabolic disorder |
| 06/20/2007 | EP1797898A1 Preventive/therapeutic drug for arteriosclerosis |
| 06/20/2007 | EP1797897A1 Medicinal composition containing meltrin antagonist |
| 06/20/2007 | EP1797891A1 Total enteral nutritious composition |
| 06/20/2007 | EP1797888A1 Ophthalmic composition containing xanthan gum and amino acid |
| 06/20/2007 | EP1797887A1 Drug for diminishing increase of neutral fat in blood after meal and food containing the same |
| 06/20/2007 | EP1797886A2 Immune stimulation using chemically modified RNA |
| 06/20/2007 | EP1797885A1 Stable combinations of amlodipine besylate and benazepril hydrochloride |
| 06/20/2007 | EP1797884A2 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 06/20/2007 | EP1797883A2 Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid |
| 06/20/2007 | EP1797882A1 Preventive and/or therapeutic medicine for rheumatoid arthritis |
| 06/20/2007 | EP1797881A1 Medicinal composition |
| 06/20/2007 | EP1797880A2 Use of P53 inhibitors for the treatment of side effects of cancer therapy |
| 06/20/2007 | EP1797879A1 Novel antimicrobial medicine |
| 06/20/2007 | EP1797878A2 Benzothiazole derivatives |
| 06/20/2007 | EP1797877A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 06/20/2007 | EP1797876A1 Combinations of vasoactive agents and their use in the treatment of sexual disfunctions |
| 06/20/2007 | EP1797875A2 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 06/20/2007 | EP1797874A1 Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation |
| 06/20/2007 | EP1797872A1 Telmisartan-containing pharmaceutical compositions for oral intake |
| 06/20/2007 | EP1797871A1 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| 06/20/2007 | EP1797869A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 06/20/2007 | EP1797858A1 Composition for oral cavity |
| 06/20/2007 | EP1797185A2 Targeting opposite strand replication intermediates of single-stranded viruses by rnai |
| 06/20/2007 | EP1797183A2 Regulation of oncogenes by micrornas |
| 06/20/2007 | EP1797115A1 A bacterial atp synthase binding domain |
| 06/20/2007 | EP1797104A1 Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them |
| 06/20/2007 | EP1797100A1 Nitrate esters and their use for mitigating cellular damage |
| 06/20/2007 | EP1797099A1 Piperidinylamino-thieno[2,3-d] pyrimidine compounds |
| 06/20/2007 | EP1797098A2 3-oxa-10-aza-phenanthrenes as pde4 or pde3/4 inhibitors |
| 06/20/2007 | EP1797096A2 Novel pyrazolopyrimidines |
| 06/20/2007 | EP1797094A2 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| 06/20/2007 | EP1797093A1 Novel 3-methyl-7-butinyl-xanthines, production thereof, and use thereof as medicaments |
| 06/20/2007 | EP1797092A1 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity |
| 06/20/2007 | EP1797091A2 Imidazoquinoline compounds |
| 06/20/2007 | EP1797089A1 Substituted tricyclic benzimidazoles |